Journal Home > Volume 1 , Issue 2
Stress and Brain 2021, 1(2): 160-172 https://doi.org/10.26599/SAB.2020.9060009
Research Article | Open Access | Issue | Published: 08 April 2021

Prevalence and risk factors for depressive symptom in methamphetamine use disorder

Show Author's Information Ziqi Liu§,  Yi Zhang§,  Ti-Fei Yuan( )
Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

§ Ziqi Liu and Yi Zhang contributed equally to this work.

Keywords:
methamphetamine use disorder, depression, abstinence days, craving
Cite this article:
Liu Z, Zhang Y, Yuan T-F. Prevalence and risk factors for depressive symptom in methamphetamine use disorder. Stress and Brain, 2021, 1(2): 160-172. https://doi.org/10.26599/SAB.2020.9060009
Download citation
EndNote(RIS)
BibTeX

1140

Views

101

Downloads

Citations

1

Crossref

N/A

WoS

N/A

Scopus

N/A

CSCD

Abstract Full text About this article
Background:

Methamphetamine use disorder (MUD) is a severe public health problem, accompanying physical and psychological impairment. Depression is a common comorbidity with MUD, which is associated with poor treatment outcome. The objective of this study is to investigate the prevalence of depressive symptoms among male MUD individuals and identify potential risk factors.

Method:

A total of 483 male MUD individuals from six drug rehabilitation centers were included for analysis. The demographic information, drug use history, and clinical performances were analyzed. We conducted multiple regression analysis to identify predictive factors of depression, and examined the difference among MUD individuals with different depression severity.

Result:

89.03% of MUD individuals exhibited depressive symptoms. Length of abstinence (β = -0.006, p = 0.003) and subjective craving (β = 0.052, p < 0.001) were the leading predictive factors of depression. Drug use onset age (R2 = 0.010, r = -0.102, p = 0.024) negatively associated with depression severity. Depressive symptoms also positively associated with anxiety (R2 = 0.171, r = 0.413, p < 0.001), poor sleep quality (R2 = 0.133, r = 0.365, p < 0.001), and impulsivity (R2 = 0.012, r = 0.111, p = 0.015).

Conclusions:

The prevalence of depressive symptoms in MUD individuals is high. Abstinence and Craving days are important predictive factors for depression severity.


menu
Abstract
Full text
Outline
About this article

Prevalence and risk factors for depressive symptom in methamphetamine use disorder

Show Author's information Ziqi Liu§, Yi Zhang§, Ti-Fei Yuan( )
Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

§ Ziqi Liu and Yi Zhang contributed equally to this work.

Abstract

Background:

Methamphetamine use disorder (MUD) is a severe public health problem, accompanying physical and psychological impairment. Depression is a common comorbidity with MUD, which is associated with poor treatment outcome. The objective of this study is to investigate the prevalence of depressive symptoms among male MUD individuals and identify potential risk factors.

Method:

A total of 483 male MUD individuals from six drug rehabilitation centers were included for analysis. The demographic information, drug use history, and clinical performances were analyzed. We conducted multiple regression analysis to identify predictive factors of depression, and examined the difference among MUD individuals with different depression severity.

Result:

89.03% of MUD individuals exhibited depressive symptoms. Length of abstinence (β = -0.006, p = 0.003) and subjective craving (β = 0.052, p < 0.001) were the leading predictive factors of depression. Drug use onset age (R2 = 0.010, r = -0.102, p = 0.024) negatively associated with depression severity. Depressive symptoms also positively associated with anxiety (R2 = 0.171, r = 0.413, p < 0.001), poor sleep quality (R2 = 0.133, r = 0.365, p < 0.001), and impulsivity (R2 = 0.012, r = 0.111, p = 0.015).

Conclusions:

The prevalence of depressive symptoms in MUD individuals is high. Abstinence and Craving days are important predictive factors for depression severity.

Keywords: methamphetamine use disorder, depression, abstinence days, craving

References(45)

[1]
Buxton, J. A., Dove, N. A. The burden and management of crystal meth use. Canadian Medical Association Journal, 2008, 178(12): 1537-1539.
DOI Google Scholar
[2]
McCann, U. D., Wong, D. F., Yokoi, F., Villemagne, V., Dannals, R. F., Ricaurte, G. A. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with [11C]WIN-35, 428. The Journal of Neuroscience, 1998, 18(20): 8417-8422.
DOI Google Scholar
[3]
Volkow, N. D., Wise, R. A., Baler, R. The dopamine motive system: Implications for drug and food addiction. Nature Reviews Neuroscience, 2017, 18(12): 741-752.
DOI Google Scholar
[4]
Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Franceschi, D., Sedler, M., Gatley, S. J., Miller, E., Hitzemann, R., Ding, Y. S. et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. The Journal of Neuroscience, 2001, 21(23): 9414-9418.
DOI Google Scholar
[5]
Robinson, T. E., Berridge, K. C. Incentive-sensitization and addiction. Addiction, 2001, 96(1): 103-114.
DOI Google Scholar
[6]
Sekine, Y., Iyo, M., Ouchi, Y., Matsunaga, T., Tsukada, H., Okada, H., Yoshikawa, E., Futatsubashi, M., Takei, N., Mori, N. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. The American Journal of Psychiatry, 2001, 158(8): 1206-1214.
DOI Google Scholar
[7]
Sekine, Y., Minabe, Y., Ouchi, Y., Takei, N., Iyo, M., Nakamura, K., Suzuki, K., Tsukada, H., Okada, H., Yoshikawa, E. et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. The American Journal of Psychiatry, 2003, 160(9): 1699-1701.
DOI Google Scholar
[8]
Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Dufour, M. C., Compton, W., Pickering, R. P., Kaplan, K. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry, 2004, 61(8): 807-816.
DOI Google Scholar
[9]
Conway, K. P., Compton, W., Stinson, F. S., Grant, B. F. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. The Journal of Clinical Psychiatry, 2006, 67(2): 247-257.
DOI Google Scholar
[10]
Glasner-Edwards, S., Marinelli-Casey, P., Hillhouse, M., Ang, A., Mooney, L. J., Rawson, R., Methamphetamine Treatment Project Corporate Authors Depression among methamphetamine users: Association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. The Journal of Nervous and Mental Disease, 2009, 197(4): 225-231.
DOI Google Scholar
[11]
Lisa, P., Felicia, K., Laura, H., Daniela, K., Marlies, R., Stefanie, N., Maik, S. J., Anne, S., Maximilian, S., Kirsi, M. et al. Associations between methamphetamine use, psychiatric comorbidities and treatment outcome in two inpatient rehabilitation centers. Psychiatry Research, 2019, 280: 112505.
DOI Google Scholar
[12]
Schmitz, J. M., Stotts, A. L., Averill, P. M., Rothfleisch, J. M., Bailley, S. E., Sayre, S. L., Grabowski, J. Cocaine dependence with and without comorbid depression: A comparison of patient characteristics. Drug and Alcohol Dependence, 2000, 60(2): 189-198.
DOI Google Scholar
[13]
Zweben, J. E., Cohen, J. B., Christian, D., Galloway, G. P., Salinardi, M., Parent, D., Iguchi, M., Project, M. T. Psychiatric symptoms in methamphetamine users. The American Journal on Addictions, 2004, 13(2): 181-190.
DOI Google Scholar
[14]
Kay-Lambkin, F. J., Baker, A. L., Lee, N. M., Jenner, L., Lewin, T. J. The influence of depression on treatment for methamphetamine use. The Medical Journal of Australia, 2011, 195(3): S38-S43.
DOI Google Scholar
[15]
Saunders, J. B., Aasland, O. G., Babor, T. F., DE LA FUENTE, J. R., Grant, M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction, 1993, 88(6): 791-804.
DOI Google Scholar
[16]
Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., Fagerstrom, K. O. The fagerström test for nicotine dependence: A revision of the fagerstrom tolerance questionnaire. British Journal of Addiction, 1991, 86(9): 1119-1127.
DOI Google Scholar
[17]
Wewers, M. E., Rachfal, C., Ahijevych, K. A psychometric evaluation of a visual analogue scale of craving for cigarettes. Western Journal of Nursing Research, 1990, 12(5): 672-681.
DOI Google Scholar
[18]
Dozois, D. J. A., Dobson, K. S., Ahnberg, J. L. A psychometric evaluation of the Beck Depression Inventory-II. Psychological Assessment, 1998, 10(2): 83-89.
DOI Google Scholar
[19]
Chen, L., Wang, L., Qiu, X. H., Yang, X. X., Qiao, Z. X., Yang, Y. J., Liang, Y. Depression among Chinese university students: Prevalence and socio-demographic correlates. PLoS One, 2013, 8(3): e58379.
DOI Google Scholar
[20]
Steer, R. A., Beck, A. T. Beck Anxiety Inventory. In: Zalaquett, C. P., Wood, R. J. (eds.), Evaluating Stress: A Book of Resources. New York: Scarecrow Education, 1997: 23-40.
[21]
Lemay, V., Hoolahan, J., Buchanan, A. Impact of a yoga and meditation intervention on students' stress and anxiety levels. American Journal of Pharmaceutical Education, 2019, 83(5): 7001.
DOI Google Scholar
[22]
Buysse, D. J., Reynolds, C. F. III, Monk, T. H., Berman, S. R., Kupfer, D. J. The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Research, 1989, 28(2): 193-213.
DOI Google Scholar
[23]
Barratt, E. S. Factor analysis of some psychometric measures of impulsiveness and anxiety. Psychological Reports, 1965, 16: 547-554.
DOI Google Scholar
[24]
Patton, J. H., Stanford, M. S., Barratt, E. S. Factor structure of the barratt impulsiveness scale. Journal of Clinical Psychology, 1995, 51(6): 768-774.
DOI
[25]
Ohayon, M. M., Hong, S. C. Prevalence of major depressive disorder in the general population of South Korea. Journal of Psychiatric Research, 2006, 40(1): 30-36.
DOI Google Scholar
[26]
Ohayon, M. M., Schatzberg, A. F. Prevalence of depressive episodes with psychotic features in the general population. The American Journal of Psychiatry, 2002, 159(11): 1855-1861.
DOI Google Scholar
[27]
Olsen, L. R., Mortensen, E. L., Bech, P. Prevalence of major depression and stress indicators in the Danish general population. Acta Psychiatrica Scandinavica, 2004, 109(2): 96-103.
DOI Google Scholar
[28]
Nakama, H., Chang, L. D., Cloak, C., Jiang, C., Alicata, D., Haning, W. Association between psychiatric symptoms and craving in methamphetamine users. American Journal on Addictions, 2008, 17(5): 441-446.
DOI Google Scholar
[29]
Wexler, B. E., Gottschalk, C. H., Fulbright, R. K., Prohovnik, I., Lacadie, C. M., Rounsaville, B. J., Gore, J. C. Functional magnetic resonance imaging of cocaine craving. The American Journal of Psychiatry, 2001, 158(1): 86-95.
DOI Google Scholar
[30]
Iudicello, J. E., Woods, S. P., Vigil, O., Cobb Scott, J., Cherner, M., Heaton, R. K., Hampton Atkinson, J., Grant, I., HIV Neurobehavioral Research Center (HNRC) Group. Longer term improvement in neurocognitive functioning and affective distress among methamphetamine users who achieve stable abstinence. Journal of Clinical and Experimental Neuropsychology, 2010, 32(7): 704-718.
DOI Google Scholar
[31]
Zorick, T., Nestor, L., Miotto, K., Sugar, C., Hellemann, G., Scanlon, G., Rawson, R., London, E. D. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction, 2010, 105(10): 1809-1818.
DOI Google Scholar
[32]
Wang, G. J., Volkow, N. D., Chang, L., Miller, E., Sedler, M., Hitzemann, R., Zhu, W., Logan, J., Ma, Y., Fowler, J. S. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. The American Journal of Psychiatry, 2004, 161(2): 242-248.
DOI Google Scholar
[33]
Rawson, R. A., Gonzales, R., Obert, J. L., McCann, M. J., Brethen, P. Methamphetamine use among treatment-seeking adolescents in Southern California: Participant characteristics and treatment response. Journal of Substance Abuse Treatment, 2005, 29(2): 67-74.
DOI Google Scholar
[34]
Mouton, M., Harvey, B. H., Cockeran, M., Brink, C. B. The long-term effects of methamphetamine exposure during pre-adolescence on depressive-like behaviour in a genetic animal model of depression. Metabolic Brain Disease, 2016, 31(1): 63-74.
DOI Google Scholar
[35]
Ohayon, M. M., Roth, T. Place of chronic insomnia in the course of depressive and anxiety disorders. Journal of Psychiatric Research, 2003, 37(1): 9-15.
DOI Google Scholar
[36]
Taylor, D. J., Lichstein, K. L., Durrence, H. H., Reidel, B. W., Bush, A. J. Epidemiology of insomnia, depression, and anxiety. Sleep, 2005, 28(11): 1457-1464.
DOI Google Scholar
[37]
Tsuno, N., Besset, A., Ritchie, K. Sleep and depression. The Journal of Clinical Psychiatry, 2005, 66(10): 1254-1269.
DOI Google Scholar
[38]
Arborelius, L., Owens, M. J., Plotsky, P. M., Nemeroff, C. B. The role of corticotropin-releasing factor in depression and anxiety disorders. The Journal of Endocrinology, 1999, 160(1): 1-12.
DOI Google Scholar
[39]
Corruble, E., Benyamina, A., Bayle, F., Falissard, B., Hardy, P. Understanding impulsivity in severe depression? A psychometrical contribution. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27(5): 829-833.
DOI Google Scholar
[40]
Ding, Y. Y., Lin, H. J., Zhou, L., Yan, H. M., He, N. Adverse childhood experiences and interaction with methamphetamine use frequency in the risk of methamphetamine-associated psychosis. Drug and Alcohol Dependence, 2014, 142: 295-300.
DOI Google Scholar
[41]
Nanni, V., Uher, R., Danese, A. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: A meta-analysis. The American Journal of Psychiatry, 2012, 169(2): 141-151.
DOI Google Scholar
[42]
Pirnia, B., Khosravani, V., Maleki, F., Kalbasi, R., Pirnia, K., Malekanmehr, P., Zahiroddin, A. The role of childhood maltreatment in cortisol in the hypothalamic-pituitary-adrenal (HPA) axis in methamphetamine-dependent individuals with and without depression comorbidity and suicide attempts. Journal of Affective Disorders, 2020, 263: 274-281.
DOI Google Scholar
[43]
Simpson, J. L., Grant, K. M., Daly, P. M., Kelley, S. G., Carlo, G., Bevins, R. A. Psychological burden and gender differences in methamphetamine-dependent individuals in treatment. Journal of Psychoactive Drugs, 2016, 48(4): 261-269.
DOI Google Scholar
[44]
Luan, X. Q., Chen, H. J., Qiu, H. H., Shen, H. P., Zhao, K., Ren, W. W., Gu, Y. Y., Su, H., Zhang, J., Lv, D. et al. Association between serum malondialdehyde levels and depression during early methamphetamine withdrawal. Neuroscience Letters, 2018, 687: 22-25.
DOI Google Scholar
[45]
Ren, W. W., Luan, X. Q., Zhang, J., Gutteea, P., Cai, Y., Zhao, J. Y., Gu, Y. Y., Wu, C. W., Su, H., Tao, J. Y. et al. Brain-derived neurotrophic factor levels and depression during methamphetamine withdrawal. Journal of Affective Disorders, 2017, 221: 165-171.
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 08 September 2020
Revised: 05 November 2020
Accepted: 28 February 2021
Published: 08 April 2021
Issue date: December 2021

Copyright

© The Author(s) 2021

Acknowledgements

The study is supported by the Guangdong grant "Key Technologies for Treatmert of Brain Disorders" (No. 2018B030331001), Modicine and Engineering Interdisciplinary Research Fund of Shanghai Jiao Tong University (No. ZH2018ZDA30), National Natural Science Foundation of China (NSFC) (Nos. 81822017 and 31771215) to T.-F. Y. We thank Jing Shen, Xi He, Hangbin Zhang, Ziqi Liu, Xue Ma, Yuxuan Zhang, Qian Zhuang, Hui Zheng, Yan Zeng, Ningning Zeng, and Di Zhao for their helps during data collection and management.

Rights and permissions

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission.

Return